PAHCPhibro Animal Health Corporation
What is the market doing?
No clear lean: rangebound and lightly shorted.
Rangebound, no clear trend. Overbought (RSI 71). Price is −8% vs its 200-day average.
Lightly shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 5.5% since the previous count, down from 3.0% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How PAHC is trading
Phibro Animal Health Corporation is −3.0% over the past year while the S&P 500 is +18%: 21 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −7.8%
vs 200-day average · below trend, but not far
- RSI (14)
- 71
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 35%
Below its 52-week high
Details›
- Last close2026-10-09
- $38.29
- 1 monthS&P 500 +2.7%
- +4.6%
- 1 yearS&P 500 +18%
- −3.0%
- 5 yearsS&P 500 +88%
- +96%
- vs 50-day average$35.95
- +6.5%
- 52-week high
- $59.33
- 52-week low
- $28.40
- Annualised volatility
- 52%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $318K
| Year | Return |
|---|---|
| 2026 (year to date) | +3.2% |
| 2025 | +81% |
| 2024 | +86% |
| 2023 | −10% |
| 2022 | −32% |
| 2021 | +7.3% |
| 2020 | −20% |
| 2019 | −21% |
| 2018 | −3.0% |
| 2017 | +16% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +0.62% |
| Feb | 10 | 9 of 10 | +9.5% |
| Mar | 10 | 6 of 10 | +1.6% |
| Apr | 10 | 7 of 10 | +3.3% |
| May | 10 | 6 of 10 | +1.2% |
| Jun | 10 | 8 of 10 | +2.7% |
| Jul | 11 | 8 of 11 | +2.2% |
| Aug | 11 | 5 of 11 | −0.17% |
| Sep | 11 | 5 of 11 | −2.1% |
| Oct | 11 | 8 of 11 | +1.4% |
| Nov | 10 | 4 of 10 | −4.0% |
| Dec | 10 | 6 of 10 | +1.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #8 of 41 by RyuScore